Skip to main navigation

Home
Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Year

February 22, 2022

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

February 22, 2022

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

January 31, 2022

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

January 25, 2022

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

January 5, 2022

Athira Pharma Provides 2022 Pipeline Outlook

November 10, 2021

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

November 10, 2021

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

November 8, 2021

Athira Pharma to Present at Upcoming Investor Conferences

October 29, 2021

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

October 22, 2021

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 41 - 50 of 93

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.